# Elranatamab in R/R Multiple Myeloma

> **NCT06138275** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT06138275
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-08
- **Primary completion:** 2026-08-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138275, "Elranatamab in R/R Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06138275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*